In fact, the treatment with a PPARγ agonist in this mouse model of CGD, resolved prolonged zymosan-induced inflammation reflected by enhanced efferocytosis, and increased TGF-β and IL-10 production, highlighting a direct association between PPARγ increased expression and improved efferocytosis34. This evidence concerns the gene PPARG and chronic granulomatous disease.